P2X7 Antagonist Piperidines for Cross-Species Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can efficiently antagonize the P2X7 receptor in both human and rodent species, with suitable drug-like properties, and can be optimally delivered to target organs affected by P2X7-mediated pathologies, including the brain.
Innovation Solution
Development of novel substituted heterocyclic compounds with P2X7 receptor antagonistic properties, specifically compounds of formula (I), which include various heterocyclic rings substituted with specific groups, and their pharmaceutically acceptable salts, solvates, and stereoisomeric forms, designed to modulate P2X7 receptor function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing P2X7 inhibitors are used, then P2X7 receptor antagonism is achieved, but species selectivity and drug-like properties are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of the heterocyclic compounds. Specifically, the invention varies the heterocyclic ring type (pyridine, pyrimidine, triazine, etc.), substituent positions, and functional groups to optimize both P2X7 receptor antagonism efficacy and species selectivity. This structural parameter optimization enables the compounds to achieve reliable antagonism in human P2X7 receptors while maintaining appropriate selectivity profiles across species.
2Reliability
If P2X7 receptor antagonism is enhanced, then therapeutic benefits increase, but delivery to target organs including brain becomes more challenging
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying the lipophilicity, molecular weight, and structural flexibility of the heterocyclic compounds. These parameter adjustments enhance blood-brain barrier penetration and distribution to inflammatory tissues, ensuring that high therapeutic efficacy at the P2X7 receptor is achieved with adequate delivery to target organs including the brain.
3Reliability
If heterocyclic compound structure is optimized for P2X7 antagonism, then receptor specificity improves, but synthesis complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the heterocyclic compound into modular components: a core heterocyclic ring (pyridine, pyrimidine, triazine, etc.), linking groups, and terminal functional groups. This modular architecture allows systematic optimization of P2X7 receptor specificity through targeted modification of individual segments while maintaining relatively simple and scalable synthesis routes for each component.
Data Source
AI summary
The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.